{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/VRTX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T18:10:51.537Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8413,"canonical_name":"VERTEX PHARMACEUTICALS INC / MA","cik":"0000875320","uei":null,"lei":null,"duns":null,"ticker":"VRTX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":39},"count":39,"timeline":[{"ts":"2026-09-01","kind":"sec.filing","form_type":"8-K","title":"8-K — VERTEX PHARMACEUTICALS INC / MA — 2026-09-01","url_slug":"/sec/cik-0000875320/8-k/0000875320-26-000264","accession_number":"0000875320-26-000264","importance":35},{"ts":"2026-08-04","kind":"sec.filing","form_type":"10-Q","title":"10-Q — VERTEX PHARMACEUTICALS INC / MA — 2026-08-04","url_slug":"/sec/cik-0000875320/10-q/0000875320-26-000259","accession_number":"0000875320-26-000259","importance":45},{"ts":"2026-08-03","kind":"sec.filing","form_type":"8-K","title":"8-K — VERTEX PHARMACEUTICALS INC / MA — 2026-08-03","url_slug":"/sec/cik-0000875320/8-k/0000875320-26-000256","accession_number":"0000875320-26-000256","importance":35},{"ts":"2026-07-21","kind":"sec.insider.a","reporter":"Sachdev Amit","title":"EVP Chief Patient & Ext Af Off","shares":8251,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-21","kind":"sec.insider.a","reporter":"Tatsis Ourania","title":"EVP, Chief Reg. & Quality Off.","shares":8251,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-07","kind":"sec.filing","form_type":"8-K","title":"8-K — VERTEX PHARMACEUTICALS INC / MA — 2026-07-07","url_slug":"/sec/cik-0000875320/8-k/0001193125-26-296710","accession_number":"0001193125-26-296710","importance":35},{"ts":"2026-07-02","kind":"sec.form144","reporter":"McKechnie Duncan","title":"Officer","shares":1541,"usd_value":799779,"security_title":"Common","approx_sale_date":"2026-07-02","accession_number":"0001959173-26-005057","importance":40.1599558},{"ts":"2026-07-02","kind":"sec.form144","reporter":"Tatsis Ourania","title":"Officer","shares":1500,"usd_value":787485,"security_title":"Common","approx_sale_date":"2026-07-02","accession_number":"0001959173-26-005073","importance":40.157497},{"ts":"2026-07-02","kind":"sec.insider.s","reporter":"McKechnie Duncan","title":"EVP, Chief Commercial Officer","shares":1541,"price_per_share":519,"usd_value":799779,"security_title":"Common Stock","importance":35.799779},{"ts":"2026-07-02","kind":"sec.insider.s","reporter":"Tatsis Ourania","title":"EVP, Chief Reg. & Quality Off.","shares":1500,"price_per_share":524.99,"usd_value":787485,"security_title":"Common Stock","importance":35.787485},{"ts":"2026-07-01","kind":"sec.form144","reporter":"Liu Joy","title":"Officer","shares":828,"usd_value":416244,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001959173-26-005009","importance":40.083248776},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Liu Joy","title":"EVP and Chief Legal Officer","shares":828,"price_per_share":502.71,"usd_value":416244,"security_title":"Common Stock","importance":35.41624388},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — Bozic Carmen — 2026-06-30","url_slug":"/sec/cik-0001790029/4/0000875320-26-000239","accession_number":"0000875320-26-000239","importance":30},{"ts":"2026-06-26","kind":"sec.form144","reporter":"Bozic Carmen","title":"Officer","shares":596,"usd_value":287570,"security_title":"Common","approx_sale_date":"2026-06-26","accession_number":"0001959173-26-004906","importance":40.057514},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Bozic Carmen","title":"EVP and CMO","shares":596,"price_per_share":482.5,"usd_value":287570,"security_title":"Common Stock","importance":35.28757},{"ts":"2026-06-18","kind":"sec.form144","reporter":"Bozic Carmen","title":"Officer","shares":1020,"usd_value":471413,"security_title":"Common","approx_sale_date":"2026-06-18","accession_number":"0001959173-26-004764","importance":40.09428268},{"ts":"2026-06-18","kind":"sec.insider.s","reporter":"Bozic Carmen","title":"EVP and CMO","shares":1020,"price_per_share":462.17,"usd_value":471413,"security_title":"Common Stock","importance":35.4714134},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Bozic Carmen","title":"Officer","shares":4062,"usd_value":1827900,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001959173-26-004654","importance":40.36558},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Bozic Carmen","title":"EVP and CMO","shares":4062,"price_per_share":450,"usd_value":1827900,"security_title":"Common Stock","importance":36.8279},{"ts":"2026-06-05","kind":"sec.form144","reporter":"Bozic Carmen","title":"Officer","shares":1745,"usd_value":785250,"security_title":"Common","approx_sale_date":"2026-06-05","accession_number":"0001959173-26-004391","importance":40.15705},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Liu Joy — 2026-06-03","url_slug":"/sec/cik-0001847529/4/0000875320-26-000230","accession_number":"0000875320-26-000230","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"Liu Joy","title":"Officer","shares":828,"usd_value":364245,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001959173-26-004191","importance":40.072849096},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Liu Joy","title":"EVP and Chief Legal Officer","shares":828,"price_per_share":439.91,"usd_value":364245,"security_title":"Common Stock","importance":35.36424548},{"ts":"2026-05-29","kind":"sec.insider.s","reporter":"Bozic Carmen","title":"EVP and CMO","shares":1974,"price_per_share":450,"usd_value":888300,"security_title":"Common Stock","importance":35.8883},{"ts":"2026-05-15","kind":"sec.form144","reporter":"Bozic Carmen","title":"Officer","shares":1354,"usd_value":613971,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001959173-26-003639","importance":40.12279426},{"ts":"2026-05-15","kind":"sec.form144","reporter":"Bunnage Mark E.","title":"Officer","shares":33,"usd_value":14964,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001959173-26-003628","importance":40.00299277},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Bozic Carmen","title":"EVP and CMO","shares":1354,"price_per_share":453.45,"usd_value":613971,"security_title":"Common Stock","importance":35.6139713},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Bunnage Mark E.","title":"EVP, Chief Scientific Officer","shares":33,"price_per_share":453.45,"usd_value":14964,"security_title":"Common Stock","importance":35.01496385},{"ts":"2026-05-13","kind":"sec.filing","form_type":"8-K","title":"8-K — VERTEX PHARMACEUTICALS INC / MA — 2026-05-13","url_slug":"/sec/cik-0000875320/8-k/0000875320-26-000204","accession_number":"0000875320-26-000204","importance":35},{"ts":"2026-05-13","kind":"sec.filing","form_type":"S-8","title":"S-8 — VERTEX PHARMACEUTICALS INC / MA — 2026-05-13","url_slug":"/sec/cik-0000875320/s-8/0000875320-26-000206","accession_number":"0000875320-26-000206","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — VERTEX PHARMACEUTICALS INC / MA — 2026-05-13","url_slug":"/sec/cik-0000875320/s-8-pos/0000875320-26-000214","accession_number":"0000875320-26-000214","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — VERTEX PHARMACEUTICALS INC / MA — 2026-05-13","url_slug":"/sec/cik-0000875320/s-8-pos/0000875320-26-000215","accession_number":"0000875320-26-000215","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — VERTEX PHARMACEUTICALS INC / MA — 2026-05-13","url_slug":"/sec/cik-0000875320/s-8-pos/0000875320-26-000216","accession_number":"0000875320-26-000216","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — VERTEX PHARMACEUTICALS INC / MA — 2026-05-13","url_slug":"/sec/cik-0000875320/s-8-pos/0000875320-26-000217","accession_number":"0000875320-26-000217","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — VERTEX PHARMACEUTICALS INC / MA — 2026-05-13","url_slug":"/sec/cik-0000875320/s-8-pos/0000875320-26-000218","accession_number":"0000875320-26-000218","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — VERTEX PHARMACEUTICALS INC / MA — 2026-05-13","url_slug":"/sec/cik-0000875320/s-8-pos/0000875320-26-000219","accession_number":"0000875320-26-000219","importance":30},{"ts":"2026-05-13","kind":"sec.filing","form_type":"S-8 POS","title":"S-8 POS — VERTEX PHARMACEUTICALS INC / MA — 2026-05-13","url_slug":"/sec/cik-0000875320/s-8-pos/0000875320-26-000220","accession_number":"0000875320-26-000220","importance":30},{"ts":"2026-05-12","kind":"sec.form144","reporter":"Bozic Carmen","title":"Officer","shares":6988,"usd_value":3144600,"security_title":"Common","approx_sale_date":"2026-05-12","accession_number":"0001959173-26-003520","importance":40.62892},{"ts":"2026-05-12","kind":"sec.insider.s","reporter":"Bozic Carmen","title":"EVP and CMO","shares":6988,"price_per_share":450,"usd_value":3144600,"security_title":"Common Stock","importance":38.1446}]}